Skip to main content

Table 3 Metabolic syndrome and hazard ratios for incident clinical endpoints

From: The clinical value of metabolic syndrome and risks of cardiometabolic events and mortality in the elderly: the Rotterdam study

Outcome

Events in population

AHA/NHLBI

IDF

EGIR

Type 2 diabetes mellitus

765/8567

3.78 (3.24–4.41)*

3.53 (3.01–4.14)*

3.13 (2.69–3.64)*

Coronary heart disease

544/7864

1.32 (1.11–1.56)*

1.38 (1.16–1.63)*

1.08 (0.87–1.35)

Stroke

458/8304

1.29 (1.07–1.56)*

1.32 (1.10–1.59)*

0.98 (0.77–1.25)

Cardiovascular mortality

418/7724

1.21 (0.99–1.47)

1.29 (1.05–1.57)*

0.95 (0.73–1.23)

All-cause mortality

2244/8586

1.10 (1.01–1.20)*

1.09 (1.01–1.19)*

1.05 (0.94–1.17)

  1. Data are presented as hazard ratios with 95 % confidence intervals. All analysis corrected for age and sex
  2. AHA/NHLBI, American heart association/national heart, lung, and blood institute; IDF, International Diabetes Federation; EGIR, European group for the study of Insulin Resistance
  3. * Statistically significant